Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique. (11th March 2019)

• Record Type: Journal Article
• Authors: Bastard, Mathieu; Molfino, Lucas; Mutaquiha, Cláudia; Galindo, Miriam Arago; Zindoga, Pereira; Vaz, Deise; Mahinça, Ivan; DuCros, Philipp; Rusch, Barbara; Telnov, Alex
• Is Part Of: Clinical infectious diseases. Volume 69:Number 10(2019)
• Page Start: 1809
• Page End: 1811
• Publication Date: 2019-03-11
• Subjects: multidrug-resistant tuberculosis -- short regimen -- bedaquiline -- treatment outcomes -- injectable drugs; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz196
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Bedaquiline was recommended by the World Health Organization as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched from injectable drug to bedaquiline suggest that a bedaquiline-based short regimen is effective and safe.